光大证券晨会速递-20250702

Group 1: New Stock Issuance and Market Trends - In June 2025, a total of 8 new stocks were listed, raising a total of 9.153 billion yuan, a month-on-month increase of 164.8% [1] - Among these, 6 stocks participated in offline issuance, raising a combined amount of 8.730 billion yuan, with a month-on-month increase of 174.1% [1] - The average first-day increase for new stocks on the main board was 188.17%, while the average for the dual-innovation board was 190.72% [1] Group 2: Pharmaceutical Industry Insights - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, aiming to transition China from a "generic drug powerhouse" to an "innovative drug stronghold" [2] - The policy is expected to promote the comprehensive prosperity of innovative drug leading companies, niche biotech sectors, and the CXO industry chain [2] - Recommended companies to watch include Heng Rui Medicine, Innovent Biologics, CanSino Biologics, WuXi AppTec, and Kelaiying [2] Group 3: Company Performance Analysis - The company, Xingsen Technology, has seen continuous revenue growth with significant long-term growth potential [4] - The profit forecast for 2025-2026 has been revised down to 112 million yuan and 271 million yuan, representing a reduction of 77% and 60% respectively [4] - A new profit forecast for 2027 has been introduced at 442 million yuan, with current stock prices corresponding to PE ratios of 196, 81, and 50 times [4]